THE Irish equity market’s 66% fall in 2008 made it the worst performer in western Europe for the second year in a row, and one of the worst markets globally.

IRISH pharmaceutical company AGI Therapeutics has seen its first half losses widen by about $1.5 million (€1.05m).

Dublin based pharmaceutical company AGI Therapeutics has announced a pre-tax loss of $7.46m (€5.2m) for the six months to the end of June 2008. This compares to a loss of $8.9m (€6.2m) the same time last year.

IRISH drug firm AGI Therapeutics has reported a widening of its full-year losses to €14.1m — up from €4.3m in 2006.

AGI Therapeutics has today reported audited financial results for the twelve months ended December 31 2007, inlcuding a net loss of €14.1m)

IEX-listed gastrointestinal drug products company AGI Therapeutics has announced net losses of €4.3m.

The Irish Stock Exchange (ISE) says it enjoyed one of its best-ever years last year.

Aer Lingus enjoyed a positive debut on the Irish stock exchange as it saw its share price jump 18c to €2.38 today.

Speciality pharmaceutical company AGI Therapeutics made a net loss of €2.3m for the half year to the end of June.

AGI Therapeutics, the Irish Stock Exchange-listed specialist drugs firm, has appointed David G Kelly as director and chief financial officer.

SHARES in AGI Therapeutics got off to a flyer on the company’s first day of trading on the Dublin and London stock markets yesterday.

Shares in AGI Therapeutics plc, a specialist pharmaceuticals company, began trading today on IEX, the Irish Stock Exchange’s specialist market for small and medium-sized companies.

A PHARMACEUTICAL company fronted by former Elan executives plans to raise over €40 million from a stock market flotation.